Experienced in Kaposi Sarcoma

Dr. James L. Gulley

Hematology Oncology
10 Center Dr., 8b08, Msc 1750, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Kaposi Sarcoma
10 Center Dr., 8b08, Msc 1750, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Gulley is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Gulley is rated as an Experienced provider by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are Prostate Cancer, Olfactory Neuroblastoma, Chordoma, Urothelial Cancer, and Orchiectomy.

His clinical research consists of co-authoring 278 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Kaposi Sarcoma.

Specialties
Hematology Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

10 Center Dr., 8b08, Msc 1750, Bethesda, MD 20892

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Biospecimen Acquisition From Human Subjects
Biospecimen Acquisition From Human Subjects
Enrollment Status: Recruiting
Publish Date: September 24, 2025
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Enrollment Status: Recruiting
Publish Date: September 04, 2025
Intervention Type: Drug, Biological
Study Drugs: Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib
Study Phase: Phase 1
Data Collection, Clinical Care and Interventions in CCR, NCI
Data Collection, Clinical Care and Interventions in CCR, NCI
Enrollment Status: Enrolling_by_invitation
Publish Date: October 07, 2025
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Enrollment Status: Completed
Publish Date: April 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug, Device, Procedure
Study Drugs: Nivolumab, Ipilimumab, PROSTVAC Shared Antigen Vaccine, Neoantigen DNA Vaccine
Study Phase: Phase 1
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 27, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 6 Less Clinical Trials

278 Total Publications

REMOVED: Referral Patterns and Barriers to Enrollment on a Trial Using HLA-A*02:01-Restricted E7 T Cell Receptor (TCR)-T Cells for Human Papillomavirus (HPV)-Associated Malignancies.
REMOVED: Referral Patterns and Barriers to Enrollment on a Trial Using HLA-A*02:01-Restricted E7 T Cell Receptor (TCR)-T Cells for Human Papillomavirus (HPV)-Associated Malignancies.
Journal: Transplantation and cellular therapy
Published: July 05, 2025
Similar Doctors
Distinguished in Kaposi Sarcoma
Dr. Richard F. Little
Hematology Oncology
Distinguished in Kaposi Sarcoma
Dr. Richard F. Little
Hematology Oncology
9609 Medical Center Dr, Room 5w426, 
Bethesda, MD 
 (0.5 miles away)
240-276-6093
Languages Spoken:
English

Richard Little is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Little is rated as a Distinguished provider by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are Kaposi Sarcoma, Castleman Disease, Multicentric Castleman Disease (MCD), Lymphoid Hyperplasia, and Bone Marrow Transplant.

Experienced in Kaposi Sarcoma
Dr. Tania Jain
Hematology Oncology | Oncology | Hematology
Experienced in Kaposi Sarcoma
Dr. Tania Jain
Hematology Oncology | Oncology | Hematology

Johns Hopkins University

5755 Cedar Ln, 
Columbia, MD 
 (18.7 miles away)
410-740-7544
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients
Offers Telehealth

Tania Jain is a Hematologist Oncology specialist and an Oncologist in Columbia, Maryland. Dr. Jain is rated as a Distinguished provider by MediFind in the treatment of Kaposi Sarcoma. Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy. Dr. Jain is currently accepting new patients.

Experienced in Kaposi Sarcoma
Dr. Aaron T. Ciner
Hematology Oncology | Hematology | Oncology
Experienced in Kaposi Sarcoma
Dr. Aaron T. Ciner
Hematology Oncology | Hematology | Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (32.4 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Ciner is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Ciner is rated as an Advanced provider by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are Bone Tumor, Myxoid Liposarcoma, Rhabdomyosarcoma Embryonal, and Fibrosarcoma. Dr. Ciner is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gulley's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile